Boosting anti-leukemia cytotoxicity of CD4 and CD8 T cells through combined inhibition of MEK and HDAC

This study investigates whether the combined inhibition of MEK and HDAC can enhance the anti-leukemia cytotoxicity of CD4 and CD8 T cells in acute myeloid leukemia (AML). The authors found that the drug combination of trametinib and quisinostat (TQ) significantly inhibited the growth of various AML cell types and improved T cell function, leading to enhanced leukemia recognition and killing. Their findings suggest that TQ not only targets AML cells but also reprograms T cells to overcome dysfunction, resulting in effective AML clearance.